AMAG is committed to supporting researchers and healthcare providers expand clinical knowledge and understanding through research and education.
Investigator-Sponsored Research (ISR)
AMAG considers requests for support of ISR involving our marketed products and/or in our therapeutic areas of expertise. AMAG can decide to provide support in funding and/or the provision of drug. AMAG receives requests for ISR support regularly and will evaluate proposals based on their scientific merit, clinical relevance and unmet medical needs.
To request review/consideration of your ISR, please complete and submit the ISR Concept Form (link below), provide a budget summary, the Principal Investigators’ CV, and send to email@example.com. Following submission of your application, a thorough review will occur generally within 30 days. The ISR Review Committee meets monthly and reviews all applications. We will then contact you to render our decision.
Click here for the ISR Concept Form/ISR Areas of Interest.
Independent Medical Education (IME)
AMAG supports IME activities in our therapeutic areas of expertise to maintain, develop or increase knowledge, skills and professional performance of healthcare providers. To request review of your IME, please complete and submit the Independent Medical Education Application (link below), and send to firstname.lastname@example.org. The IME Review Committee meets monthly and reviews all applications. Your application must be received at least 60 days prior to the event in order to be considered. Please include a summary of your request on your institutional letterhead accompanied by an IRS W9 form, Proof of Accreditation (ACCME, ACPE, or other) via certificate, detailed budget, and tentative agenda. We will then contact you to inform you of our decision.
Click here for IME Areas of Interest
Click here for IME Application
Annual Research Grants to Address Prematurity & Preeclampsia
Through our maternal health grants program, AMAG supports independent researchers making important strides in identifying ways to reduce preterm birth rates and associated complications. The company is pleased to announce that it will again be funding research grants in prematurity and preeclampsia in 2020 for a total of $250,000.